发现强效和实用的抗血管原剂,灵感来自于皮质素A
Barbara Czakó1, László Kürti, Akiko Mammoto
1Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, Massachusetts 02138, USA.
Journal of the American Chemical Society
|May 28, 2009
概括
新的类固醇化合物显示出强大的抗血管性活性,在小鼠模型中抑制了血管生长. 这些简单的水溶性药物可以治疗湿斑变性和其他依赖血管生成的疾病.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 眼科医生 眼科 眼科
背景情况:
- 科尔蒂斯塔丁A和J具有显著的抗血管性质.
- 血管新生,新血管的形成,与诸如湿斑变性等疾病有关.
- 基于类固醇的化合物为开发新疗法提供了潜在的途径.
研究的目的:
- 为了研究更简单,更容易合成的类固醇衍生物对抗血管新生活性.
- 开发强效,水溶性化合物用于治疗血管生成依赖性疾病.
- 评估眼湿性黄斑变性病的治疗潜力.
主要方法:
- 新型类固醇基化合物的合成.
- 在小鼠视网膜血管生成模型中测试一种化合物.
- 对人类静脉内皮细胞 (HUVECs) 中血管内皮生长因子 (VEGF) 诱导的细胞迁移的抑制作用的评估.
主要成果:
- 开发了几种强效,水溶性抗血管生成化合物.
- 一种化合物在小鼠中抑制了视网膜血管生成,剂量为500 pmol.
- 与皮质素A相比,合成化合物显示出更强的抑制VEGF诱导的HUVEC迁移.
结论:
- 新型类固醇衍生物具有显著的抗血管性潜力.
- 这些化合物适合在治疗湿斑变性时局部应用.
- 开发的化合物为各种血管生成依赖疾病提供了有前途的治疗策略.
相关概念视频
Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...


